|
Studies measuring markers of endothelium activation in patients with or at risk for ARDS |
|||||
| Investigator |
Patients Controls |
Biomarker / Summary |
ROC curve analysis Cut-off values |
Specificity – Sensitivity PPV-NPV |
Limitations |
|
|
|||||
| Donnelly et al. 39 |
82 at risk 14 ARDSa 62 controls |
E-selectin levels were not correlated with ARDS development and patients' mortality. L-selectin levels exhibited a significant prognostic value |
No |
Not estimated |
Heterogeneity of studied population (trauma-sepsis) No ROC curve analysis / cut-off levels No serial measurement |
| Boldt et al. 40 |
50 at risk |
Constantly lower E-selectin, ICAM-1 and VCAM-1 levels in survivors experiencing polytrauma than in nonsurvivors |
No |
Not estimated |
Small sample size Causal diversity of patient group No definitive association with patients' mortality No ROC curve analysis / cut-off levels |
| Cowley et al. 41 |
40 SIRS 85 controls |
Superiority of E-selectin plasma levels in predicting organ dysfunction and death patients with SIRS comparing to ICAM-1 |
No |
Not estimated |
Small number of patients Causal diversity of patients studied No ROC curve analysis / cut-off levels |
| Sessler et al. 43 |
25 at risk 12 controls |
Association of elevated ICAM-1 Sequential plasma levels with the severity of shock |
Yes ICAM-1: 715 ng/ml (predicting survival) |
Not reported |
Small sample size Heterogeneity of studied population Inconclusive association with disease Severity |
| Kayal et al. 44 |
32 at risk 9 controls |
Cut off values of E-selectin, ICAM-1 and VWF serum levels predicted survival outcome |
Yes E-selectin: 128 ng/ml ICAM-1: 715 ng/ml VWF: 717% |
E-selectin: 73-80-67-85% ICAM-1: 80-90-75-92% VWF: 87-8080-87% |
Small number of patients Most of the patients developed secondary ALI |
| Agouridakis et al. 45 |
23 ARDSa 42 at risk |
TNFa, IL-1, ICAM-1, VCAM-1 ICAM-1 and VCAM-1 showed a high NPV for ARDS development Correlation with the disease outcome None of the studied markers was an independent factor for ARDS development |
Yes TNFa: 325 pg/ml IL-1: 225 pg/ml ICAM-1: 300 pg/ml VCAM-1: 260 pg/ml |
For ARDS development TNFa: 62-75-38-89% IL-1: 58-88-39-94% ICAM-1: 69-75-42-90% VCAM-1: 73-88-50-95% |
Small sample size No serial measurement None of the studied markers was an independent factor for ARDS development |
|
Abbreviations: ALI: Acute Lung Injury, ARDS: Acute Respiratory Distress Syndrome, ICAM-1: Intercellular Cell Adhesion Molecule-1, IL: Interleukin, ROC: Receiver Operating Characteristic, SIRS: Systematic Inflammatory Response Syndrome, TNFa: Tumor Necrosis Factor-alpha, VCAM-1: Vascular Cell Adhesion Molecule-1, VWF: von Willebrand factor antigen, a: Use the American European Consensus Conference definitions | |||||
Tzouvelekis et al. Respiratory Research 2005 6:62 doi:10.1186/1465-9921-6-62 |
|||||